Form 4: Cognition Therapeutics CFO John Brendan Doyle Reports Tax-Related Stock Disposal
SEC Form 4 Filing
Chief Financial Officer of Cognition Therapeutics, John Brendan Doyle, reports the disposal of 1,723 common stock shares to cover tax withholding obligations.
Summary
- On February 15, 2025, John Brendan Doyle, the Chief Financial Officer of Cognition Therapeutics Inc. (CGTX), disposed of 1,723 shares of common stock.
- The disposal was conducted to cover tax withholding obligations related to the vesting of restricted stock units.
- The shares were disposed of at a price of $0.5901 per share.
- Following the transaction, Doyle directly owns 414,402 shares of Cognition Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to tax obligations, so it has a neutral sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 02/15/2025 | Date of stock disposal transaction. |
| 02/18/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.